Ancillary Study for DD Laquinimod Clinical Trial

Investigator: Scott Zamvil, MD, PhD
Sponsor: Teva Pharmaceutical Industries, Ltd.

Location(s): United States


A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by an active treatment period, to evaluate the efficacy, safety and tolerability of two doses of oral administration of laquinimod (0.6 mg/day or 1.2 mg/day) in subjects with relapsing remitting multiple sclerosis (RRMS)